| 1 |
Kannaka K, Sano K, Munekane M, Yamasaki T, Hagimori M, Mukai T. Enhanced Therapeutic Effect of Liposomal Doxorubicin via Bio-Orthogonal Chemical Reactions in Tumors. Mol Pharmaceutics. [DOI: 10.1021/acs.molpharmaceut.1c00936] [Reference Citation Analysis]
|
| 2 |
Wahab S, Alshahrani MY, Ahmad MF, Abbas H. Current trends and future perspectives of nanomedicine for the management of colon cancer. Eur J Pharmacol 2021;910:174464. [PMID: 34474029 DOI: 10.1016/j.ejphar.2021.174464] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 3 |
Chang CH, Chang MC, Chang YJ, Chen LC, Lee TW, Ting G. Translating Research for the Radiotheranostics of Nanotargeted 188Re-Liposome. Int J Mol Sci 2021;22:3868. [PMID: 33918011 DOI: 10.3390/ijms22083868] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 4 |
Pei P, Liu T, Shen W, Liu Z, Yang K. Biomaterial-mediated internal radioisotope therapy. Mater Horiz 2021;8:1348-66. [DOI: 10.1039/d0mh01761b] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 5 |
Cytryniak A, Nazaruk E, Bilewicz R, Górzyńska E, Żelechowska-Matysiak K, Walczak R, Mames A, Bilewicz A, Majkowska-Pilip A. Lipidic Cubic-Phase Nanoparticles (Cubosomes) Loaded with Doxorubicin and Labeled with 177Lu as a Potential Tool for Combined Chemo and Internal Radiotherapy for Cancers. Nanomaterials (Basel) 2020;10:E2272. [PMID: 33207760 DOI: 10.3390/nano10112272] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 6 |
Zheng L, Shen CL, Li JM, Ma YL, Yan N, Tian XQ, Zhao YZ. Assessment of the Preventive Effect Against Diabetic Cardiomyopathy of FGF1-Loaded Nanoliposomes Combined With Microbubble Cavitation by Ultrasound. Front Pharmacol 2019;10:1535. [PMID: 31998132 DOI: 10.3389/fphar.2019.01535] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 7 |
Kleynhans J, Grobler AF, Ebenhan T, Sathekge MM, Zeevaart J. Radiopharmaceutical enhancement by drug delivery systems: A review. Journal of Controlled Release 2018;287:177-93. [DOI: 10.1016/j.jconrel.2018.08.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 8 |
Lan L, Liu H, Smith AR, Appelman C, Yu J, Larsen S, Marquez RT, Wu X, Liu FY, Gao P, Gowthaman R, Karanicolas J, De Guzman RN, Rogers S, Aubé J, Neufeld KL, Xu L. Natural product derivative Gossypolone inhibits Musashi family of RNA-binding proteins. BMC Cancer 2018;18:809. [PMID: 30097032 DOI: 10.1186/s12885-018-4704-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 9 |
Eh Suk VR, Misran M. Development and Characterization of DOPEPEG2000 Coated Oleic Acid Liposomes Encapsulating Anticancer Drugs. J Surfact Deterg 2017;20:321-9. [DOI: 10.1007/s11743-016-1914-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 10 |
Shen YA, Lan KL, Chang CH, Lin LT, He CL, Chen PH, Lee TW, Lee YJ, Chuang CM. Intraperitoneal 188Re-Liposome delivery switches ovarian cancer metabolism from glycolysis to oxidative phosphorylation and effectively controls ovarian tumour growth in mice. Radiotherapy and Oncology 2016;119:282-90. [DOI: 10.1016/j.radonc.2016.02.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 11 |
Huang FY, Lee TW, Chang CH, Chen LC, Hsu WH, Chang CW, Lo JM. Evaluation of 188Re-labeled PEGylated nanoliposome as a radionuclide therapeutic agent in an orthotopic glioma-bearing rat model. Int J Nanomedicine 2015;10:463-73. [PMID: 25624760 DOI: 10.2147/IJN.S75955] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
|
